We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
The Fantasy Football Hub brings together some of the very best fantasy football players, bloggers, toll creators, podcasters, and content creators under roof. The company has a social media presence of more than 3,000 paying subscribers. It has more than 24,000 Twitter followers and 7,000 YouTube subscribers. FHH's monetisation strategy is based on three streams: Site memberships, Generic site advertising, and Affiliate partnerships. With the proceeds, the company will provide additional player and team analysis tools, improve its website user interface, and increasing developer man-hours.
days to go: Expired investment: £109,056
Ensuring an organisation's activities are compliant with key regulations. Evidology is a software program that can be easily integrated into a business's existing infrastructure. The software will check the business's data against more than 40 local and international legislation's and provide a real-time report to management that will highlight whether the business is following compliance, or not. Evidology's revenue model consists of a 3-year subscription package, in the form of a standard, or enterprise-level product. The company has tested their software within nine businesses, including HSBC. Evidology has predicted to break even as soon as 15 months, based on selling their product at a modest rate of 3 clients per month.
days to go: Expired investment: £50,003
Created in 2015, Fourex provides an advanced and innovative self-service kiosk for exchanging over 150 currencies in both coins and notes. The company has grown its revenue by 175 % and it is continuing to grow. It will be live in 80 locations by the end of 2019. Fourex has a presence at Heathrow, Gatwick, and Stansted with access to 153 million passengers per year. It is located in 21 London underground stations with a combined 1.9 million passengers each day. In early 2018, Fourex has extended its business from 12 locations to 66 locations. It has won innovation awards from Lloyds Bank, Virgin, and Amazon. The company's revenue has increased by 175% in 2 years. Fourex's current partners are TfL/London, Westfield, Underground, Welcome Break, Intu, Moto and Roadchef. The company aims to become a principal multi-currency exchange solution. With the proceeds, the company will be accelerating its growth in the UK, by expanding the network of machines nationwide both in international travel hubs, high footfall retails and transit locations.
days to go: Expired investment: £928,830
Nebeus aims to bridge the gap between cryptocurrency and cash, providing people with instant crypto-backed cash services for everyday use. The company argues that there is an equivalent of $400 billion held in more than 55 million crypto wallets around the world which cannot be used further than keeping as an investment. It aims to change this scenario. Nebeus's core product is its 'Instant Loans' offering. It also offers users to do mobile top-ups, conduct Card2Card transfers, and send cash to Points of Sale (PoS) amongst other financial services. The company is working to come out with a 'Nebeus Mastercard' in partnership with Railsbank in Q1 of 2021. Nebeus has more than 60,000 users on its portal and has overseen transactions over £30 million to date. The company has featured in publications like The Independent, Forbes, and Bloomberg to name a few. It will use the investment for growth and marketing, the rollout of Nebeus Mastercard rollout, for growing its team, and for Research and Development (R&D).
days to go: Expired investment: £862,580
SoundOut is an online product testing company that enables retailers to optimise their ranges and improve their forecasting. They do this by crowdsourcing millions of reviews and ratings from consumers.  
days to go: Expired investment: £363,745
Enoron is a management system that allows lawyers to easily manage all their clients and all their related information, all their matters and deadlines, keeping track of all their activities, timesheets and accounting and much more.
days to go: Expired investment: £31,896
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph